Key changes to the Atrium Evolution Series – Diversified Fund PDS and TMDs effective 17 October 2025

We wish to inform you that we are making the below key changes to the Product Disclosure Statement (PDS) for the Atrium Evolution Series – Diversified Fund (Fund) effective 17 October 2025.

We suggest that you read this flyer and speak to your financial adviser to assess whether this information affects your investment decisions.

Capitalised terms used in this document have the same meaning as in the PDS.

Key changes to the Fund’s PDS

The key changes to the Fund’s PDS include, but are not limited to, the following:

  1. Updated disclosure of fees and costs – While there have been no changes to the fee structure that applies to the Fund, our estimates of certain fees and costs have been updated following our latest review to ensure that they accurately reflect the costs of managing the Fund.
    .
  2. Adoption of a marketing name for the Fund – The Fund is adopting a marketing name to better align with Atrium’s unique ‘Risk Targeted’ investment philosophy. This name change will also be reflected in the Fund’s TMDs and any other factsheets and marketing materials. The Fund’s registered name and Australian Registered Scheme Number (ARSN), being the Atrium Evolution Servies – Diversified Fund (ARSN 151 191 776), will remain unchanged.
    .
    The Fund’s new marketing name is set out in the table below:
    .
    Table 1: Adoption of marketing name

    .
  3. Changes to the names of the Fund’s Unit Classes – The names of each of the Fund’s Unit Classes are changing to better align with Atrium’s unique ‘Risk Targeted’ investment philosophy.
    .
    The changes to the Fund’s Unit Class names are set out in the table below:
    .
    Table 2: Name changes to the Fund’s unit classes

    .
  4. Change to the wording of the investment objective and the inclusion of certain RBA return objectives for each Sub-Trust Portfolio – The wording of the investment objective for each Sub-Trust Portfolio has changed to include:
    .
    • an explicit return objective within the wording of the investment objective; and
    • explicit return objectives for each of the Sub-Trust Portfolios.
    .
    Importantly, it should be noted that there are no changes to the targets that the Fund is managed to, no changes to the benchmarks used for performance reporting, and no fundamental changes to the Fund’s underlying investment objective or investment strategy.The Manager is of the view that these changes will provide clearer information for investors as they will improve transparency, set a measurable return benchmark for investors, and link expected returns more explicitly to the risk levels investors have chosen.

    The change to the investment objective is set out in the table below:

    Table 3: Change to investment objective wording

    The inclusion of explicit Return Objectives for each Sub-Trust Portfolio are set out in the table below:

    Table 4: Inclusion of Return Objectives for each Sub-Trust Portfolio

    * Each Portfolio’s Return Objective is stated net of fees and costs.

  5. Change to the definition of ‘Dealing Day’– The following changes will occur from 17 October 2025:

    • the Fund’s unit pricing will be calculated and published on a daily basis (rather than on a weekly basis as is currently the case); and

    • in order to implement daily unit pricing, the definition of a ‘Dealing Day’ in the PDS (which is applicable to applications, withdrawals, transfers and unit pricing calculations for the Fund) will change to mean each ‘Business Day’.

  6. New cut-off time for investor requests – requests for applications, withdrawals, transfers, etc., must be received and accepted by the Unit Registry before 10:00am (Sydney time) on a Dealing Day (i.e., each Business Day) in order for the relevant request to be processed using the Unit Price for that Dealing Day.

Full details of the abovementioned changes can be found in the updated PDS. As always, we recommend that you read the PDS carefully, along with the Target Market Determinations (TMDs) for each of the Fund’s Unit Classes, to understand the main benefits and risks of investing, along with other features of the Fund. The updated TMDs for the Fund will be issued in tandem with the updated PDS on 17 October 2025.

Full details of the abovementioned changes can be found in the updated PDS and TMDs listed below:

Atrium Evolution Risk Targeted PDS

Atrium Evolution Risk Targeted – AEF 5 – TMD

Atrium Evolution Risk Targeted – AEF 7 – TMD

Atrium Evolution Risk Targeted – AEF 7 P – TMD

Atrium Evolution Risk Targeted – AEF 9 – TMD

Atrium Evolution Risk Targeted – AEF 9 P – TMD

Queries

If you have any queries relating to the information provided in this notice, please contact Atrium via:

Telephone: (02) 9248 8090

Email: investors@atriuminvest.com.au

Website: www.atriuminvest.com.au

Disclaimer: This notice contains general information only and is not intended to provide you with financial advice. This notice has been prepared without taking into account your objectives, financial situation or needs. You should consider whether the information is suitable for your circumstances and we recommend that you seek professional advice. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information.

Important Information

This information has been prepared and issued by Atrium Investment Management Pty Ltd (ABN 17 137 088 745, AFSL 338 634) (Atrium) as the investment manager of the Marketing Name: Atrium Evolution Risk Targeted Fund. Registered Name: Atrium Evolution Series – Diversified Fund (ARSN151 191 776), Integrated Managed Account Portfolio Service (ARSN 627 688 402) (MAPS) and the Colonial First State Separately Managed Account (ARSN 618 390 051) (CFS SMA).

The information is general information only and is not intended to provide you with financial advice and has been prepared without taking into account your objectives, financial situation or needs. You should consider the product disclosure statement (PDS), prior to making any investment decisions. The PDS and target market determination (TMD) can be obtained by visiting our website atriuminvest.com.au. If you require financial advice that takes into account your personal objectives, financial situation or needs, you should consult your licensed or authorised financial adviser. his information is only as current as the date indicated, and may be superseded by subsequent market events or for other reasons. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. All investments contain risk and may lose value.

The Trust Company (RE Services) Limited (ABN 45 003 278 831, AFSL 235150) is the Responsible Entity (RE) of the Atrium Evolution Series – Diversified Fund (ARSN 151 191 776), Integrated Managed Account Portfolio Service (ARSN 627 688 402) (MAPS), Atrium Enhanced Fixed Income Fund (ARSN 616 127112) and Atrium Alternatives Fund (ARSN 616 126 982). Investors should consider the PDS and TMD (available from Atrium’s website) before making any investment decisions.

Colonial First State Investments Limited (ABN 98 002 348 352, AFSL 232468 ) is the Responsible Entity (RE) of the Colonial First State Separately Managed Account (ARSN 618 390 051) (CFS SMA). Atrium is the portfolio manager of each of the aforementioned portfolios. Investors should consider the relevant offering document (Product Disclosure Statement (PDS) or Information Memorandum (IM) as appropriate), Target Market Determination (TMD) and other relevant information available from Atrium before making any investment decision. Investments in the CFS SMA are only available on CFS Edge. Investors should consider the PDS and TMD before making any investment decisions. Applications for a portfolio in the CFS SMA can only be made pursuant to the application form attached to the relevant PDS or Investor Directed Portfolio Service (IDPS) guide (CFS SMA Offer Documents). Please refer to the CFS SMA Offer Documents for important information concerning an investment in the CFS SMA.

You can only invest in MAPS through HUB24 Invest, an IDPS operated and administered by HUB24 Custodial Services Ltd (ABN 94 073 633 664, AFSL239122) (HUB24 Custodial Services), or through HUB24 Super, a super investment service offered through the HUB24 Super Fund (ABN 60 910 190 523, RSER1074659, USI 60 910 190 523 001) (‘Nominated Platform’ means either HUB24 Invest or HUB24 Super). HUB24 Custodial Services is the promoter of theHUB24 Super Fund and provides a range of services to the HUB24 Super Fund. Investors should consider the MAPS PDS and TMD (available from the Nominated Platform’s and Atrium’s website) before making any investment decision. Please refer to the disclosure documents for your Nominated Platform(available from your financial adviser or your Nominated Platform) together with the PDS for important information concerning an investment in MAPS.

Search for